# Phase 1 sclerosis trials recruiting: 53 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 53 trials in phase 1 for sclerosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 sclerosis trials: 53 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/sclerosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 53
- Recruiting or not yet: 53
- Read on: November 19, 2026

## Trials

The 25 newest of 53, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07935031 | A Study of IMS001 in Patients With Multiple Sclerosis | Zhuhai Hengqin ImStem Biotechnology Co., Ltd. | Phase 1 | Recruiting | Multiple Sclerosis | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935031) |
| October 30, 2026 | NCT07906665 | A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS) | Sachi Bioworks Inc. | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906665) |
| October 20, 2026 | NCT07883590 | A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS). | Eli Lilly and Company | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883590) |
| October 15, 2026 | NCT07875972 | Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS) | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875972) |
| September 24, 2026 | NCT07838389 | Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS) | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | ALS - Amyotrophic Lateral Sclerosis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838389) |
| June 30, 2026 | NCT07676266 | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | The Affiliated Hospital of Qingdao University | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676266) |
| May 26, 2026 | NCT07606521 | A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus | Polpharma Biologics International AG | Phase 1 | Not yet recruiting | Multiple Sclerosis | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07606521) |
| May 15, 2026 | NCT07589764 | Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS | Duke University | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis ALS | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589764) |
| May 14, 2026 | NCT07587125 | Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis | Xijing Hospital | Phase 1 | Recruiting | Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis, Multiple Sclerosis (MS) Secondary Progressive... | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07587125) |
| May 6, 2026 | NCT07571200 | A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) | Eli Lilly and Company | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07571200) |
| May 6, 2026 | NCT07571174 | A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | Eli Lilly and Company | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07571174) |
| May 1, 2026 | NCT07562074 | Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis | University of Calgary | Phase 1 | Not yet recruiting | Multiple Sclerosis, Depression - Major Depressive Disorder, Fatigue | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562074) |
| April 13, 2026 | NCT07526493 | Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological... | Tongji Hospital | Phase 1 | Recruiting | Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE), Chronic... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07526493) |
| April 13, 2026 | NCT07523100 | A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis. | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523100) |
| February 10, 2026 | NCT07401121 | Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis | Celosia Therapeutics Pty Ltd | Phase 1 | Recruiting | ALS (Amyotrophic Lateral Sclerosis) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07401121) |
| January 27, 2026 | NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | SAPU NANO (US) LLC | Phase 1 | Recruiting | Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC)... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369505) |
| January 14, 2026 | NCT07341828 | A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy | Huashan Hospital | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341828) |
| December 26, 2025 | NCT07304154 | Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment | Kite, A Gilead Company | Phase 1 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07304154) |
| December 17, 2025 | NCT07290062 | A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic... | Insmed Gene Therapy LLC | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07290062) |
| December 8, 2025 | NCT07270120 | Senolytics for Secondary Progressive MS | Ohio State University | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS) Secondary Progressive | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07270120) |
| November 4, 2025 | NCT07224373 | An Open-label Study of AZD0120 in Adults With Multiple Sclerosis | AstraZeneca | Phase 1 | Recruiting | Multiple Sclerosis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224373) |
| October 28, 2025 | NCT07221799 | OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis | University of Maryland, Baltimore | Phase 1 | Not yet recruiting | Multiple Sclerosis, Neuropathic Pain | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221799) |
| October 27, 2025 | NCT07221240 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis | PRG Science & Technology Co., Ltd. | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221240) |
| October 3, 2025 | NCT07204977 | Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis, Motor Neuron Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07204977) |
| August 24, 2025 | NCT07139743 | Obe-cel in Refractory Progressive Forms of Multiple Sclerosis | Autolus Limited | Phase 1 | Recruiting | Progressive Multiple Sclerosis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07139743) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 4 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 2 |
| Ractigen Therapeutics. | 1 |
| St. Petersburg State Pavlov Medical University | 1 |
| Duke University | 1 |
| PRG Science & Technology Co., Ltd. | 1 |
| 1ST Biotherapeutics, Inc. | 1 |
| Insmed Gene Therapy LLC | 1 |
| Xijing Hospital | 1 |
| Sachi Bioworks Inc. | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| Xalud Therapeutics, Inc. | 1 |
| University of Calgary | 1 |
| Rennes University Hospital | 1 |
| Autolus Limited | 1 |
| National Cancer Institute (NCI) | 1 |
| Stanford University | 1 |
| The Foundation for Orthopaedics and Regenerative Medicine | 1 |
| Brain Trust Bio | 1 |
| SAPU NANO (US) LLC | 1 |
| Tongji Hospital | 1 |
| Yale University | 1 |
| Xuanwu Hospital, Beijing | 1 |
| University of Alabama at Birmingham | 1 |
| Huashan Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 24 |
| China | 10 |
| Canada | 10 |
| Australia | 7 |
| Germany | 5 |
| Spain | 5 |
| Belgium | 3 |
| Netherlands | 3 |
| France | 3 |
| Israel | 2 |
| United Kingdom | 2 |
| Russia | 1 |
| South Korea | 1 |
| Greece | 1 |
| Brazil | 1 |
| Czechia | 1 |
| Poland | 1 |
| Romania | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sawmills in the United States](https://specstream.ai/data/businesses/sawmills/united-states)
- [Irrigation contractors in the United States](https://specstream.ai/data/businesses/irrigation-contractors/united-states)
- [Concierge medicine practices in the United States](https://specstream.ai/data/businesses/concierge-medicine-practices/united-states)
- [Vehicle shipping companies in the United States](https://specstream.ai/data/businesses/vehicle-shipping-companies/united-states)
- [Osteopathic practices in the United States](https://specstream.ai/data/businesses/osteopathic-practices/united-states)
- [Financial services firms in the United States](https://specstream.ai/data/businesses/financial-services-firms/united-states)
